Development of CAR T cells designed to improve antitumor efficacy and safety
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Chimeric antigen receptor (CAR) T cell therapy has shown promising efficacy against hematologic malignancies. Antitumor activity of CAR T cells, however, needs to be improved to increase therapeutic efficacy in both hematologic and solid cancers. Limitations to overcome are ‘on-target, off-tumor’ toxicity, antigen escape, short CAR T cell persistence, little expansion, trafficking to the tumor and inhibition of T cell activity by an inhibitory tumor microenvironment. Here we will discuss how optimizing the design of CAR T cells through genetic engineering addresses these limitations and improves the antitumor efficacy of CAR T cell therapy in pre-clinical models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447 · cited 2×
“…(ipilimumab) or PD-1 (nivolumab and pembrolizumab) have been successful in patients with metastatic melanoma (Larkin et al., 2015; Wolchok et al., 2013) and non-small cell lung cancer (Borghaei et al., 2015; Brahmer et al., 2015; Garon et al., 2015) and are being tested in many other cancer types.”
BackgroundPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198 · cited 2×
“…(ipilimumab) or PD-1 (nivolumab and pembrolizumab) have been successful in patients with metastatic melanoma (Larkin et al., 2015; Wolchok et al., 2013) and non-small cell lung cancer (Borghaei et al., 2015; Brahmer et al., 2015; Garon et al., 2015) and are being tested in many other cancer types.”
BackgroundChimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413 · cited 1×
“However, in spite of this success in B-ALL patients, a subset of patients that achieve complete remission relapses with CD19-negative leukemia (Grupp et al., 2013; Lee et al., 2015; Maude et al., 2014).”
ResultNivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230 · cited 2×
“…that block CTLA-4 (ipilimumab) or PD-1 (nivolumab and pembrolizumab) have been successful in patients with metastatic melanoma (Larkin et al., 2015; Wolchok et al., 2013) and non-small cell lung cancer (Borghaei et al., 2015; Brahmer et al., 2015; Garon et al., 2015) and are being tested in many…”
BackgroundChimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509 · cited 1×
“However, in spite of this success in B-ALL patients, a subset of patients that achieve complete remission relapses with CD19-negative leukemia (Grupp et al., 2013; Lee et al., 2015; Maude et al., 2014).”
ResultMolecular mechanisms of T cell co-stimulation and co-inhibition
Chen, L., & Flies, D. B. (2013) · Nature Reviews Immunology · doi:10.1038/nri3405 · Cited by 3,114
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898 · cited 1×
“However, in spite of this success in B-ALL patients, a subset of patients that achieve complete remission relapses with CD19-negative leukemia (Grupp et al., 2013; Lee et al., 2015; Maude et al., 2014).”
ResultImmune-related adverse events with immune checkpoint blockade: a comprehensive review
Michot, J. M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.016 · Cited by 2,127 · cited 1×
“Treatment with checkpoint inhibitors can cause severe immune-related adverse events, which can be treated with steroids or anti-TNFα antibodies (Michot et al., 2016).”
BackgroundBrentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063 · cited 8×
“CD19 CAR T cells target normal B-cells, leading to B-cell aplasia (Brentjens et al., 2011, 2013; Kalos et al., 2011; Porter, Levine, Kalos, Bagg, & June, 2011), which can be treated with monthly infusions of immunoglobulin.”
BackgroundSelf-citation
Cited by
Combination strategies to maximize the benefits of cancer immunotherapy
Zhu, S., Zhang, T., Zheng, L., Liu, H., Song, W., Liu, D., Li, Z., & Pan, C.-X. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01164-5 · Cited by 654
“Combination with immune modulators In order to create an immunostimulatory milieu, CAR-T cells can be combined with other immunostimulatory molecules, such as immunostimulatory cytokines, cytokine receptors and co-stimulatory molecules, or even modified to directly express these molecules as seen in the fourth generat…”
BackgroundMetabolites and the Tumour Microenvironment: From Cellular Mechanisms to Systemic Metabolism
Elia, I., & Haigis, M. C. (2021) · Nature Metabolism · doi:10.1038/s42255-020-00317-z · Cited by 651
Immunotherapy in ovarian cancer
Odunsi, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx444 · Cited by 384
A guide to manufacturing CAR T cell therapies
Vormittag, P., Gunn, R., Ghorashian, S., & Veraitch, F. S. (2018) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2018.01.025 · Cited by 383
Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant
Yang, C., Xia, B.-R., Zhang, Z.-C., Zhang, Y.-J., Lou, G., & Jin, W.-L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.577869 · Cited by 350
Metadata
- Authors
- Jaspers, J. E., & Brentjens, R. J.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2017-10
- Volume
- 178
- Pages
- 83-91
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2603662360
- Cited by
- 107
- References
- 24
- FWCI
- 5.92
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Development of CAR T cells designed to improve antitumor efficacy and safety. https://app.cochat.ai/papers/10.1016/j.pharmthera.2017.03.012
- The paper
- Jaspers, J. E., & Brentjens, R. J. (2017). Development of CAR T cells designed to improve antitumor efficacy and safety. Pharmacology & Therapeutics. https://doi.org/10.1016/j.pharmthera.2017.03.012
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.